Sichuan Kelun Pharmaceutical (SHE:002422), through its subsidiaries, granted Switzerland-based Windward Bio the right to commercialize a anti-thymic stromal lymphopoietin worldwide, according to a Monday filing with the Shenzhen Stock Exchange.
The anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) SKB378/HBM93781, which is intended to treat pulmonary diseases, was developed by Harbour Biopharmaceuticals Holdings, one of the pharmaceutical company's subsidiaries that signed the commercial deal with Sichuan Kelun Botai Biopharmaceutical.
Harbour Biopharma, which is also the drug's licensor, is eligible to receive upfront and milestone payments of up to $970 million, as well as tiered royalties ranging from single-digit to double-digit percentages based on net sales. The upfront and near-term payments amount to $45 million, including cash consideration and equity in Windward Bio's parent company, the filing added.
Harbour Biopharma is also eligible to receive additional payments if Windward Bio undergoes a change in company control or enters into a sublicense agreement with a third party.
The agreement came after Windward Bio raised $200 million from its latest Series A fundraising round led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.